Marker Therapeutics (MRKR) Receivables - Net (2022 - 2025)
Marker Therapeutics (MRKR) has disclosed Receivables - Net for 4 consecutive years, with $600000.0 as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Net rose 100.0% to $600000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $600000.0, a 100.0% increase, with the full-year FY2024 number at $9.5 million, up 3066.67% from a year prior.
- Receivables - Net was $600000.0 for Q3 2025 at Marker Therapeutics, up from $12000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $9.5 million in Q4 2024 to a low of $12000.0 in Q2 2025.
- A 4-year average of $1.8 million and a median of $900000.0 in 2024 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: surged 3066.67% in 2024, then crashed 94.0% in 2025.
- Marker Therapeutics' Receivables - Net stood at $2.0 million in 2022, then plummeted by 85.0% to $300000.0 in 2023, then soared by 3066.67% to $9.5 million in 2024, then crashed by 93.68% to $600000.0 in 2025.
- Per Business Quant, the three most recent readings for MRKR's Receivables - Net are $600000.0 (Q3 2025), $12000.0 (Q2 2025), and $9.5 million (Q4 2024).